These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 31409760

  • 1. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
    Wang J, Wei H, Huang Y, Chen D, Zeng G, Lian Y, Huang Y.
    Aging (Albany NY); 2019 Aug 13; 11(15):5769-5785. PubMed ID: 31409760
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 3. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 4. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 01; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 5. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 31; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 7. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma.
    Li X, Zhou Y, Yang L, Ma Y, Peng X, Yang S, Li H, Liu J.
    J Cell Physiol; 2020 Apr 31; 235(4):3402-3413. PubMed ID: 31549407
    [Abstract] [Full Text] [Related]

  • 8. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
    Wang TT, Hong YF, Chen ZH, Wu DH, Li Y, Wu XY, Huang HQ, Zhang Q, Jia CC.
    Biochem Biophys Res Commun; 2021 Jun 18; 558():14-21. PubMed ID: 33894673
    [Abstract] [Full Text] [Related]

  • 9. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
    Turcios L, Chacon E, Garcia C, Eman P, Cornea V, Jiang J, Spear B, Liu C, Watt DS, Marti F, Gedaly R.
    PLoS One; 2019 Jun 18; 14(2):e0212538. PubMed ID: 30794613
    [Abstract] [Full Text] [Related]

  • 10. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
    Hong M, Almutairi MM, Li S, Li J.
    Phytomedicine; 2020 Mar 18; 68():153174. PubMed ID: 31991293
    [Abstract] [Full Text] [Related]

  • 11. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C, Lin LI, Cheng YC, Feng ZR, Shao YY, Cheng AL, Ou DL.
    Clin Cancer Res; 2016 May 15; 22(10):2555-64. PubMed ID: 26603262
    [Abstract] [Full Text] [Related]

  • 12. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N, Ye R, He Q, Guo P, Chen H, Zhang Q.
    Oncol Rep; 2018 Dec 15; 40(6):3235-3248. PubMed ID: 30272354
    [Abstract] [Full Text] [Related]

  • 13. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system.
    Wu SY, Lan SH, Wu SR, Chiu YC, Lin XZ, Su IJ, Tsai TF, Yen CJ, Lu TH, Liang FW, Li CY, Su HJ, Su CL, Liu HS.
    Hepatology; 2018 Jul 15; 68(1):141-154. PubMed ID: 29328502
    [Abstract] [Full Text] [Related]

  • 14. Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells.
    Kwon HY, Kim JH, Kim B, Srivastava SK, Kim SH.
    Arch Toxicol; 2018 Jan 15; 92(1):241-257. PubMed ID: 28676953
    [Abstract] [Full Text] [Related]

  • 15. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ, Hsu SM, Chien CY, Wang YH, Hsu MH, Suk FM.
    Molecules; 2020 Jun 20; 25(12):. PubMed ID: 32575795
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo CM, Man K, Ding J, Lee TK, Ma S.
    J Hepatol; 2018 Oct 20; 69(4):826-839. PubMed ID: 29885413
    [Abstract] [Full Text] [Related]

  • 17. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
    Zhao F, Feng G, Zhu J, Su Z, Guo R, Liu J, Zhang H, Zhai Y.
    Anticancer Drugs; 2021 Apr 01; 32(4):386-393. PubMed ID: 33395067
    [Abstract] [Full Text] [Related]

  • 18. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 19. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.
    Wang W, Lin H, Liu D, Wang T, Zhu Z, Yu P, Zhang J.
    Cancer Sci; 2024 Sep 06; 115(9):2923-2930. PubMed ID: 39014520
    [Abstract] [Full Text] [Related]

  • 20. Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.
    Xiao MC, Qian H, Huang CK, Zheng BN, Yan FZ, Liu F, Zhang X, Chen SJ, Luo C, Xie WF.
    Eur J Pharmacol; 2021 Sep 05; 906():174217. PubMed ID: 34087223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.